ORGANOGENESIS HOLDINGS INC. (ORGO) Debt Components
- 2024-12-31: Secured Debt, CurrentUSD (m); Secured DebtUSD $0.00; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2024-09-30: Secured Debt, CurrentUSD $5.96M; Secured DebtUSD $62.34M; Long-term DebtUSD $62.34M; Long-Term Debt, Maturity, Year OneUSD $6.56M.
- 2024-06-30: Secured Debt, CurrentUSD $5.76M; Secured DebtUSD $63.75M; Long-term DebtUSD $63.75M; Long-Term Debt, Maturity, Year OneUSD $6.56M.
- 2024-03-31: Secured Debt, CurrentUSD $5.49M; Secured DebtUSD $65.16M; Long-term DebtUSD $65.16M; Long-Term Debt, Maturity, Year OneUSD $6.56M.
ORGANOGENESIS HOLDINGS INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Secured Debt, Current USD | Secured Debt USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Notes Payable, Current USD | Long-term Debt, Excluding Current Maturities USD | Long-term Line of Credit USD | Notes Payable USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Line of Credit Facility, Average Outstanding Amount USD | Line of Credit Facility, Unused Capacity, Commitment Fee Percentage pure | Line of Credit Facility, Remaining Borrowing Capacity USD | Line of Credit Facility, Periodic Payment USD | Debt Instrument, Collateral Amount USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Unamortized Discount, Current USD | Debt Instrument, Unamortized Discount, Noncurrent USD | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $5.96M | $62.34M | $62.34M | $6.56M | $54.38M | $1.41M | $227.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $5.76M | $63.75M | $63.75M | $6.56M | $54.38M | $2.81M | $261.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $5.49M | $65.16M | $65.16M | $6.56M | $54.38M | $4.22M | $296.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $5.49M | $66.56M | (m) | (m) | (m) | (m) | $332.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $66.56M | $5.62M | $6.56M | (m) | (m) | (m) | (m) | (m) | (m) | $54.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $5.48M | $67.97M | $67.97M | $1.41M | $5.62M | (m) | $369.00K | (m) | (m) | $0.00 | (m) | $6.56M | $54.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $5.48M | $69.38M | $69.38M | $2.81M | $5.62M | (m) | $406.00K | (m) | (m) | $0.00 | (m) | $6.56M | $54.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $5.01M | $70.31M | $70.31M | $3.75M | $5.62M | (m) | $444.00K | (m) | (m) | $0.00 | (m) | $6.56M | $54.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $4.54M | $71.25M | (m) | (m) | (m) | (m) | $481.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $71.25M | $4.69M | $5.62M | (m) | (m) | (m) | (m) | (m) | (m) | $6.56M | $54.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $5.00M | $73.12M | $73.12M | $1.88M | $4.69M | (m) | $521.00K | (m) | (m) | $0.00 | (m) | $5.62M | $6.56M | $54.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $3.60M | $73.12M | $73.12M | $1.88M | $4.69M | (m) | $560.00K | (m) | (m) | $0.00 | (m) | $5.62M | $6.56M | $54.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $3.13M | $73.59M | $73.59M | $2.34M | $4.69M | (m) | $598.00K | (m) | (m) | $0.00 | (m) | $5.62M | $6.56M | $54.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $2.66M | $74.06M | (m) | (m) | (m) | (m) | $637.00K | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $74.06M | (m) | $2.81M | (m) | (m) | (m) | (m) | (m) | (m) | $4.69M | $5.62M | $6.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $2.19M | $74.53M | $74.53M | $469.00K | $2.81M | (m) | $678.00K | (m) | (m) | $0.00 | (m) | $4.69M | $5.62M | $60.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $22.50M | (m) | $70.00M | $11.25M | $22.50M | (m) | (m) | (m) | (m) | (m) | (m) | $22.50M | $13.75M | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $16.88M | (m) | $70.00M | $11.25M | $22.50M | (m) | (m) | (m) | (m) | (m) | (m) | $22.50M | $13.75M | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $16.67M | $60.00M | (m) | (m) | (m) | (m) | $290.00K | (m) | (m) | $10.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $70.00M | $16.67M | $20.00M | (m) | (m) | (m) | (m) | (m) | (m) | $20.00M | $13.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $11.67M | (m) | $99.35M | (m) | $16.67M | (m) | (m) | (m) | (m) | (m) | (m) | $20.00M | $20.00M | $42.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $6.67M | (m) | $99.35M | (m) | $16.67M | (m) | (m) | (m) | (m) | (m) | (m) | $20.00M | $20.00M | $42.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $1.67M | (m) | $93.48M | (m) | $16.67M | (m) | (m) | (m) | (m) | (m) | (m) | $20.00M | $20.00M | $36.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $366.00K | $0.00 | $49.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $50.00M | $0.00 | $13.89M | $0.00 | (m) | (m) | (m) | (m) | (m) | $16.67M | $16.67M | $2.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $635.00K | $40.00M | $0.00 | $12.22M | $0.00 | (m) | (m) | $39.66M | $33.48M | (m) | $13.33M | $13.33M | $1.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $338.00K | (m) | (m) |
| 2019-03-31 | (m) | $635.00K | $40.00M | $0.00 | $12.22M | $0.00 | (m) | (m) | $39.63M | $30.98M | (m) | $13.33M | $13.33M | $1.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $365.00K | (m) | (m) |
| 2019-03-15 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.25% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $762.00K | $2.54M | (m) | (m) | $15.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $26.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.52M | (m) | (m) | (m) | (m) | (m) | $762.00K | (m) |
| 2018-12-31 | (m) | $635.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.45M | (m) | (m) | (m) | (m) | (m) |
| 2018-08-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $850.00K | (m) | (m) | (m) |
| 2018-05-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $600.00K | (m) | (m) | (m) |
| 2017-12-31 | (m) | $635.00K | $52.14M | (m) | (m) | (m) | (m) | $0.00 | (m) | $17.62M | $15.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.65M | $57.49M | (m) | (m) | $1.08M | $5.34M |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $100.00K | (m) | (m) | (m) |
| 2017-08-11 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $300.00K | (m) | (m) | (m) |
| 2017-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $2.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $375.00K | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |